156 related articles for article (PubMed ID: 8928455)
1. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
Podol'tseva EI; Morozova EV; Almazov VA
Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
[TBL] [Abstract][Full Text] [Related]
2. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
4. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
6. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
7. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
[TBL] [Abstract][Full Text] [Related]
10. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
11. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
Franco M; Fuzibet JG; Cassuto JP; Pesce A; Ziegler G; Dujardin P
Rev Rhum Mal Osteoartic; 1985 Nov; 52(11):619-23. PubMed ID: 3909365
[TBL] [Abstract][Full Text] [Related]
12. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
13. International Staging System required standardization of biochemical laboratory testing in multiple myeloma.
Tichý M; Maisnar V; Palicka V; Friedecký B; Vávrová J; Novotná H; Cermáková Z; Dastych M; Cechák P; Vogtová D; Jarolímková E; Benáková H; Hachová L; Bezdícková D; Kouril F; Zábranská EA; Zenková J; Slabý P; Scudla V; Gregora E; Spicka I; Straub J; Schützova M; Hájek R
Neoplasma; 2006; 53(6):492-4. PubMed ID: 17167717
[TBL] [Abstract][Full Text] [Related]
14. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
16. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
18. [Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 May; 37(5):479-87. PubMed ID: 1842146
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
20. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]